Gossamer Bio宣布高达2.5亿美元的私募配售 (GOSS:纳斯达克)
· seekingalpha.com
Gossamer Bio (GOSS)计划进行一项2.5亿美元的私募配售,与seralutinib的肺动脉高压新药申请(PAH NDA)及FDA里程碑相关。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...